Voyageur Pharmaceuticals

Voyageur Pharmaceuticals Inc. is a Calgary-based company focused on becoming a global leader in medical imaging contrast media creating advanced stage projects with raw material mineral resources 100% owned by Voyageur. Voyageur is targeting the over $4.7 billion global market for contrast agents used in diagnostic imaging procedures.

The company is developing barium and iodine-based contrast products for computed tomography (CT), fluoroscopy and magnetic resonance imaging (MRI). Voyageur’s lead product is SmoothX, an oral barium sulfate suspension for abdominal CT imaging with an estimated total market potential of $188.5 in North America. Additional pipeline products are in various stages of development for imaging of the gastrointestinal system and vasculature.

Voyageur has secured exclusive access to high-purity barium sulfate and iodine mineral deposits in Canada and the United States. The company is integrating near-term manufacturing agreements with third parties and constructing its own future processing plant to achieve vertical integration. 

Voyageur’s strategy is to produce high-quality contrast agents at low cost by leveraging its proprietary natural resources. The company aims to obtain regulatory clearances and launch multiple products commercially in the coming years to address the growing global demand for essential medical imaging contrast media products.